Sector News

Lilly and Merus partner to develop T-Cell re-directing antibody therapies

January 23, 2021
Life sciences

Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.

Under the partnership, Merus’ Biclonics platform will be used alongside Loxo Oncology at Lilly’s scientific and rational drug design expertise to research and develop up to three CD3-engaging antibody therapies.

Merus will lead the discovery and early stage research while Loxo Oncology at Lilly will oversee additional research, development and commercialisation of the therapies.

Loxo Oncology at Lilly chief operating officer Jacob Van Naarden said: “CD3-engaging bispecific antibodies are rapidly becoming one of the most transformative immune-modulating modalities used to treat cancer.

“Merus has built a differentiated platform and one that we believe can enable us to create bispecific antibody therapies with wider therapeutic indexes than those available today.”

Merus will receive an upfront cash payment of $40m and an equity investment by Lilly worth $20m in Merus common shares.

In addition, Merus is eligible to get up to $540m per product as in potential development and commercialisation milestone payment, totalling to approximately $1.6bn for three products.

On Lilly successfully marketing a therapy from the partnership, Merus will receive tiered royalties in mid-single to low-double digits on product sales.

Merus president and CEO Bill Lundberg said: “The collaboration with Loxo Oncology at Lilly and their world-class research capabilities opens up exciting possibilities for Merus’ Biclonics platform.

“Our CD3 T-cell engager platform includes over 175 novel and diverse anti-CD3 common light chain antibodies across a wide range of affinities and attributes and enables functional screening of large libraries for optimal performance.”

Last month, Eli Lilly signed a definitive agreement to acquire biotechnology company Prevail Therapeutics for a total consideration of up to $26.50 per share in cash or approximately $1.04bn.

by Pharmaceutical-Technology.com

Source: pharmaceutical-technology.com

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).